Lilly Q2 2026 revenue rises 48% to $22.97B; 2026 revenue guidance raised to $85-87B

Lilly reported second-quarter 2026 revenue of $22,974 million, up 48%, driven by volume growth of 60% that more than offset a 13% drop in realized prices. Mounjaro sales rose 91% to $9,943 million and Zepbound rose 46% to $4,928 million. The company raised full-year revenue guidance to $85.0-87.0 billion, but the non-GAAP EPS range narrowed to $35.50-36.50 because a $3.03 per-share acquired IPR&D charge offset the operating raise.

• Q2 revenue $22,974M, up 48% from $15,558M
• Mounjaro $9,943M (+91%); Zepbound $4,928M (+46%)
• Reported EPS $7.94; non-GAAP EPS $8.38, including a $3.03 IPR&D charge
• 2026 revenue guidance $85.0-87.0B, up from $82-85B
• 2026 non-GAAP EPS guidance $35.50-36.50, down from $35.50-37.00 at the top end